Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation

Trial Profile

Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Stomatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Innovation Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 Results presented in an Innovation Pharmaceuticals media release.
    • 11 Dec 2017 Primary endpoint (Incidence of severe oral mucositis (WHO Grade 3)) has been met according to an Innovation Pharmaceuticals media release.
    • 26 Oct 2017 Status changed from active, no longer recruiting to completed, according to an Innovation Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top